AbCellera Biologics Inc. (ABCL) Institutional Ownership

Ownership Summary

The institutional landscape for AbCellera Biologics Inc. (NASDAQ:ABCL) includes 140 filers as of the latest reporting cycle ending September 2025.

• AbCellera Biologics saw its institutional ownership percentage fell to 34.8% in September 2025 from 35.1% in June 2025.
• Quarterly data indicates a 10.70% shift in institutional share volume, and the annual owner count reflects an increase of 2.19%.
• A review of institutional activity for AbCellera Biologics shows 75 of 140 filers increasing their positions, while 38 reduced their stake, and 27 remained unchanged.
• Collectively, institutional investors increased their stake in AbCellera Biologics to 104.14Mn shares as of September 2025, a change that is up by 10.06Mn shares quarter on quarter and up 1.07Mn shares year over year.
• The top institutional stake in AbCellera Biologics as of September 30, 2025 belongs to BAKER BROS. ADVISORS LP, which owns 27.53Mn shares, or 9.21% of the company.
• Among the most significant buyers of AbCellera Biologics during September 2025 were BANK OF AMERICA CORP /DE/ (2.19Mn), MORGAN STANLEY (1.80Mn), DRIEHAUS CAPITAL MANAGEMENT LLC (1.23Mn), TWO SIGMA INVESTMENTS, LP (1.06Mn), SUSQUEHANNA INTERNATIONAL GROUP, LLP (824.25K).
• Leading sellers of AbCellera Biologics stock in September 2025 included MILLENNIUM MANAGEMENT LLC (967.85K), UBS Group AG (958.73K), CITADEL ADVISORS LLC (805.86K), PIER 88 INVESTMENT PARTNERS LLC (135.31K), Graham Capital Management, L.P. (116.92K).
• The top 10 institutional holders of AbCellera Biologics for the quarter ending September 2025 included BAKER BROS. ADVISORS LP (27.53Mn), Capital World Investors (13.36Mn), BAILLIE GIFFORD & CO (10.42Mn), TWO SIGMA INVESTMENTS, LP (5.18Mn), TWO SIGMA ADVISERS, LP (4.80Mn), ArrowMark Colorado Holdings LLC (4.11Mn), BlackRock, Inc. (3.64Mn), RENAISSANCE TECHNOLOGIES LLC (3.36Mn), MORGAN STANLEY (2.79Mn), TANG CAPITAL MANAGEMENT LLC (2.60Mn).